| 4.76 -0.12 (-2.46%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.3 |
1-year : | 7.36 |
| Resists | First : | 5.4 |
Second : | 6.3 |
| Pivot price | 3.27 |
|||
| Supports | First : | 3.73 |
Second : | 2.71 |
| MAs | MA(5) : | 3.85 |
MA(20) : | 3.25 |
| MA(100) : | 2.8 |
MA(250) : | 2.22 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 82.4  |
D(3) : | 82.6 |
| RSI | RSI(14): 77.2 |
|||
| 52-week | High : | 5.4 | Low : | 1.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TSHA ] has closed It is unclear right now based on current values. 320.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.41 - 5.44 | 5.44 - 5.46 |
| Low: | 4.42 - 4.45 | 4.45 - 4.48 |
| Close: | 4.71 - 4.76 | 4.76 - 4.8 |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Fri, 03 Oct 2025
Could Taysha's FDA Alignment Fast-Track Its BLA Submission? - RTTNews
Thu, 02 Oct 2025
Taysha Gene Therapies Inc. (TSHA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Thu, 02 Oct 2025
Taysha Gene Therapies (TSHA) Stock Soars 52% After FDA Grants Breakthrough Therapy Designation for Rett Syndrome - parameter.io
Thu, 02 Oct 2025
Taysha Gene Therapies: Shares Are Soaring On FDA Alignment, But Caution Is Advised - Seeking Alpha
Thu, 02 Oct 2025
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday - Benzinga
Thu, 02 Oct 2025
Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 273 (M) |
| Held by Insiders | 1.7343e+008 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 36,410 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.801e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 347 % |
| Return on Equity (ttm) | -20.9 % |
| Qtrly Rev. Growth | 8.1e+006 % |
| Gross Profit (p.s.) | 81.03 |
| Sales Per Share | -53.47 |
| EBITDA (p.s.) | 8.35052e+006 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -82 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 5.07 |
| Dividend | 0 |
| Forward Dividend | 4.336e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|